Eye Movement Abnormalities Are Ubiquitous in the Spinocerebellar Ataxias.


Journal

Cerebellum (London, England)
ISSN: 1473-4230
Titre abrégé: Cerebellum
Pays: United States
ID NLM: 101089443

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 9 6 2019
medline: 11 4 2020
entrez: 9 6 2019
Statut: ppublish

Résumé

Oculomotor abnormalities are common in the spinocerebellar ataxias (SCAs). In studies of SCAs 1, 2, 3, and 6, eye movement abnormalities correlate with disease severity. Oculomotor abnormalities may be the sole motor manifestation of early and/or premanifest disease; however, not all ataxia rating scales include oculomotor assessment. We sought to identify the prevalence and characteristics of oculomotor abnormalities at first presentation in a large SCA cohort, including those in earlier stages of disease. We performed a retrospective assessment of initial clinical examinations of SCA patients followed in the Massachusetts General Hospital Ataxia Unit and assessed with the Brief Ataxia Rating Scale (BARS). One hundred thirty-four SCA patients were assessed: 17 SCA1, 13 SCA2, 55 SCA3, 2 SCA5, 22 SCA6, 11 SCA7, 9 SCA8, and 5 SCA17, mainly in the early stages of disease (67.2% stage 0-1). Oculomotor abnormalities were present on initial assessment in 94.8%, including 7/9 stage 0 and 77/81 stage 1 patients. Stage 0/1 patients had frequent saccadic intrusions, nystagmus, and hypo/hypermetric saccades. Saccadic slowing was present even in early stage SCA7 and SCA2, eventually leading to ophthalmoplegia. The burden of oculomotor abnormalities correlated with disease stage, duration, and severity, remaining highly significant even when controlling for age. The ubiquitous presence of oculomotor abnormalities in the SCAs, particularly early in the course, underscores the importance of oculomotor assessment in ataxia rating scales such as BARS. These findings highlight the potential for quantitative physiological oculomotor measures as clinical biomarkers in natural history studies and clinical trials.

Identifiants

pubmed: 31175630
doi: 10.1007/s12311-019-01044-2
pii: 10.1007/s12311-019-01044-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1130-1136

Références

Neurology. 2015 Jul 7;85(1):96-103
pubmed: 26062625
Front Neurol. 2011 Sep 01;2:53
pubmed: 21909334
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Brain. 1998 Apr;121 ( Pt 4):589-600
pubmed: 9577387
Cerebellum. 2013 Jun;12(3):418-28
pubmed: 23090211
Mov Disord. 2013 Aug;28(9):1271-7
pubmed: 23609488
Neurology. 2006 Jun 13;66(11):1711-6
pubmed: 16769945
BMC Neurol. 2014 Jan 22;14:17
pubmed: 24450306
Clin Neurophysiol. 2009 Mar;120(3):632-5
pubmed: 19201647
Arch Neurol. 1998 Oct;55(10):1353-7
pubmed: 9779665
J Neuroophthalmol. 2015 Mar;35(1):16-21
pubmed: 25259863
Mov Disord. 2009 Sep 15;24(12):1820-8
pubmed: 19562773
Curr Opin Neurol. 2014 Feb;27(1):75-82
pubmed: 24300789

Auteurs

Christopher D Stephen (CD)

Ataxia Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge St, Suite 2000, Boston, 02114, MA, United States. cstephen@mgh.harvard.edu.
Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. cstephen@mgh.harvard.edu.

Jeremy D Schmahmann (JD)

Ataxia Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge St, Suite 2000, Boston, 02114, MA, United States. jschmahmann@mgh.harvard.edu.
Laboratory for Neuroanatomy and Cerebellar Neurobiology, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. jschmahmann@mgh.harvard.edu.
Cognitive Behavioral Neurology Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. jschmahmann@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH